(Q35172183)

6 August 2017

1 reference

title

Immunomodulation for treatment and prevention of atherosclerosis (English)

1 reference

6 August 2017

2

Yehuda Shoenfeld

1 reference

6 August 2017

1

Yaniv Sherer

1 reference

6 August 2017

publication date

1 February 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

1-2

1 reference

6 August 2017

page(s)

21-27

1 reference

Atherosclerosis — An Inflammatory Disease

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Artherosclerosis as an infectious, inflammatory and autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Immunomodulation of atherosclerosis: myth and reality.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Autoantibody against oxidised LDL and progression of carotid atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Immunomodulation of various autoimmune diseases by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

IFN-gamma potentiates atherosclerosis in ApoE knock-out mice

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Interferon-γ elicits arteriosclerosis in the absence of leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

IL-8 is an angiogenic factor in human coronary atherectomy tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Interleukin-8 and its receptor CXCR2 in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900003-9

7 January 2021

10.1016/S1568-9972(01)00003-9

Identifiers

DOI

1 reference

6 August 2017

1 reference